Results 41 to 50 of about 1,222 (146)

Clinical–radiological–pathological correlation in chronic thromboembolic pulmonary hypertension

European Respiratory Review, 2023
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-threatening complication of acute pulmonary embolism. It is characterised by persistent fibro-thrombotic pulmonary vascular obstructions and elevated pulmonary artery ...
Tom Verbelen, Laurent Godinas, Peter Dorfmüller, Deepa Gopalan, Robin Condliffe, Marion Delcroix   +5 more
doaj   +1 more source

Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension [PDF]

Thorax, 1999
Considerable progress has been made in the diagnosis and management of acute pulmonary thromboembolism (PTE) but there are few data about the true incidence, early mortality, and long term progress of this condition. Recurrent PTE or incomplete resolution of the initial event leading to the development of secondary pulmonary hypertension is even less ...
J, Dunning, K, McNeil
openaire   +2 more sources

A novel rat model of pulmonary artery embolism and the application value of lung ultrasound B‐lines in early‐stage pulmonary embolism

Animal Models and Experimental Medicine, EarlyView.
We report a novel embolus‐induced PE rat model prepared via the inferior vena cava under ultrasound guidance. The embolus employed featured a tubular plastic casing filled with thrombus. By minimizing the contact surface between plasmin and thrombus, it effectively restrains the elevated plasmin activity in rats.
Huide Ma, Shuangrui Wang, Honghui Li, Yaxing Zhang, Yuman Gao, Jie Zhou, Xia Xu, Rong Wu   +7 more
wiley   +1 more source

Pulmonary arteriovenous malformation in chronic thromboembolic pulmonary hypertension

Indian Journal of Radiology and Imaging, 2016
Chronic thromboembolic pulmonary hypertension is a morbid condition associated with complications such as hemoptysis, right heart failure, paradoxical embolism, and even death.
Arun Sharma, Gurpreet S Gulati, Neeraj Parakh, Abhinav Aggarwal   +3 more
doaj   +1 more source

Prophylactic Enoxaparin Reduces Symptomatic Venous Thromboembolism Compared With No Chemoprophylaxis Within 95 Days After Knee Arthroscopy

Arthroscopy, EarlyView.
Purpose To investigate whether prophylactic use of low‐molecular‐weight heparin (enoxaparin) after knee arthroscopy reduces the incidence of symptomatic venous thromboembolism (VTE) compared with no postoperative pharmacological prophylaxis. Methods We conducted a population‐based cohort study using linked national insurance and hospital data from ...
Aylin Albrecht, Lorenz Kapral, Felix Gruber, Christoph Dibiasi, Oliver Kimberger, Christian Albrecht   +5 more
wiley   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

Should We Change the Target of Therapy in Pulmonary Hypertension?

Life, 2023
Despite the evolution of drug therapy in pulmonary arterial hypertension and the more aggressive treatment approach according to the guidelines, patients continue to have unacceptable mortality rates.
Panagiotis Karyofyllis, Eftychia Demerouti, Pavlos Habibis, Styliani Apostolopoulou, Eleftheria-Garyfallia Tsetika, Dimitrios Tsiapras   +5 more
doaj   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

EmPHasis‐10 Health‐Related Quality of Life and Exercise Capacity in Chronic Thromboembolic Pulmonary Hypertension After Balloon Angioplasty

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Whether pulmonary hemodynamic parameters and functional capacity are associated with quality of life in patients with chronic thromboembolic pulmonary hypertension remains unknown.
Hayato Sakamoto, Ayumi Goda, Kazuki Tobita, Kaori Takeuchi, Hanako Kikuchi, Takumi Inami, Yuichi Tamura, Takashi Kohno, Shin Yamada, Kyoko Soejima, Toru Satoh   +10 more
doaj   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source